Navigation Links
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Date:8/6/2008

SS (Positive and Negative Symptom Scale) Excited Component (PEC) score, measured at two hours after the first dose. Various assessments of a patient's agitation state were conducted at serial time points using standard agitation scales over the first 4-hour post- dose time period, with follow-up assessments at the end of the 24-hour study period. Side effects were recorded throughout the 24-hour period. The Company expects to release initial results of this trial before the end of September 2008.

A second Phase 3 clinical trial was initiated in July 2008 and is designed to enroll approximately 300 patients diagnosed with bipolar I disorder and acute agitation at 18 U.S. clinical centers. The trial is an in-clinic, multicenter, randomized, double-blind, placebo-controlled study and will test AZ-004 at two dose levels, 5 and 10 mg. Patients may receive up to three doses of study drug in a 24-hour period, depending on their clinical status. Patients eligible for the study include those who are admitted through an emergency department and those who are already in-patients in a hospital setting, as long as they have acute agitation at the time of patient randomization. This study is the first AZ-004 study enrolling bipolar disorder patients. The Company projects that this second Phase 3 clinical trial will take approximately 12 months to complete patient enrollment. The primary endpoint for the study is the change from baseline in the PEC score, measured at two hours after the first dose. Various assessments of a patient's agitation state will be conducted at serial time points using standard agitation scales over the first 4-hour post-dose time period, with follow-up assessments at the end of the 24-hour study period. Side effects will be recorded throughout the 24-hour period. AZ-004 has been licensed to Symphony Allegro, Inc., or Symphony Allegro, and Alexza has the right to repurchase all rights to this product candidate.

-- AZ-001 (Staccato prochlorper
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... TOKIO , July 13, 2014 /PRNewswire/ ... Juli in Tokio ... der firmenseitigen Bemühungen zur Neuausrichtung seines Forschungsrahmenprogramms. ... umfassenden Überblick über die fortgeschrittenen klinischen Programme ... Das Ziel der Tagung bestand darin, aktuelle ...
(Date:7/13/2014)...  Eli Lilly and Company (NYSE: ... study in genetically engineered mice examining combination therapy ... N3pG and beta-secretase inhibitor BACE (LY2811376). Data results ... removing clumps of amyloid-beta protein in the brain ... to Alzheimer,s disease (AD) – than use of ...
(Date:7/11/2014)... /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced a new ... in portable vaporizers, which contains CBD, or cannabodiol. ... cannabidiol offers consumers a THC-free product made for ... technology. Photo - http://photos.prnewswire.com/prnh/20140711/126344 ... compounds which are currently known, two of which ...
Breaking Medicine Technology:Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2
... July 26 Halt Medical, Inc. announced ... been appointed to its Scientific Advisory Board.  Dr. Rubin ... to develop and implement comprehensive reimbursement strategies.  Dr. Rubin,s ... of medicine, government, and business. Currently, he is Clinical ...
... Reportlinker.com announces that a new market research report is available in its ... 2008 U.S. Diabetes Drug Delivery - ... http://www.reportlinker.com/p0236248/2008-US-Diabetes-Drug-Delivery---Patient-Perspective.html , ... This study encompasses feedback provided by U.S. diabetes patients ...
Cached Medicine Technology:Dr. Robert J. Rubin to Join Halt Board as Reimbursement Advisor 22008 U.S. Diabetes Drug Delivery - Patient Perspective 22008 U.S. Diabetes Drug Delivery - Patient Perspective 32008 U.S. Diabetes Drug Delivery - Patient Perspective 42008 U.S. Diabetes Drug Delivery - Patient Perspective 5
(Date:7/13/2014)... Genetics identifies a novel genetic and molecular ... (EoE), opening up potential new therapeutic strategies for ... EoE is a chronic inflammatory disorder of the ... to certain foods and an over-accumulation in the ... of the body,s immune system). EoE can cause ...
(Date:7/13/2014)... inexpensive, portable, microchip-based test for diagnosing type-1 diabetes ... better understand the disease, according to the device,s ... , Described in a paper to be published ... the test employs nanotechnology to detect type-1 diabetes ... the two main forms of diabetes mellitus, which ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Chromatography ... biological components from various types of biological samples ... separate the sample mixture into two phase, namely ... the mobile phase run over the stationary phase, ... the components that provide the separation of mixture. ...
(Date:7/13/2014)... Recently, MillionaireCasket.com, a well-known casket manufacturer from China, has ... the company’s chief executive officer has announced a new promotion ... offered at discounted prices, from 15 to 26 percent off. ... in huge demand in the current market. We are excited ... a lot of high quality products for sale. Many of ...
(Date:7/13/2014)... Vancouver, BC (PRWEB) July 13, 2014 ... creating excitement by promoting the rental of bikes for ... the historic downtown Victorian Hotel to tour the area ... day, plus tax. Bicycle enthusiasts love to call Vancouver ... many options for cycle travel and picturesque journeys through ...
Breaking Medicine News(10 mins):Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2
... the Y chromosome uses a neat trick to repair its ... from rotting away over evolutionary time. ,The Y chromosome, of ... makes males rather than females. ,Some scientists have suggested ... can't eliminate genetic defects in the usual way,// and broken ...
... Health Organisation said the world should be free of the ... but warned the disease could emerge in China again next ... within the next two-to-three weeks. SARS will be gone, we ... the only two areas still regarded as zones where the ...
... the onset of prostate cancer, however, finasteride may also ... men were randomized , age 55 or older to ... examination results were normal in all subjects, and prostate-specific ... Among the 4368 men in the finasteride group treated ...
... about something, let it out and it might save ... headaches internalize their anger more than those without headaches. ... study, 171 suffered from headaches. Investigators measured //trait anger ... hostility, anxiety and depression. Participants also provided information about ...
... vitamin D. ,Each year, 200,000 women in the United States ... form of the vitamin may enhance the effect of radiation ... with radiation alone to mice exposed to both radiation and ... tumor volume in those women treated //with EB 1089 was ...
... is most likely to be deadly when tumor cells spread ... a protein that may be able to predict a tumor’s ... ,Researchers from the University of Michigan Comprehensive Cancer Center are ... cancer cells to leave their original location and enter nearby ...
Cached Medicine News:Health News:Y chromosome uses trick to repair its own genes 2Health News:World SARS-free within weeks 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: